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Abstract
Background: Coronary heart disease (CHD) is typically associated with many cardiovascular risk factors (e.g.,
elevated blood pressure), low health-related quality of life, depression, anxiety and psychological stress. Expressive
writing (EW) has shown beneficial effects on such variables in both people from the community and in patients
with a variety of chronic illnesses. However, no study to date has evaluated the physical and psychological effects
of the expressive writing procedure on coronary patients referred to cardiac rehabilitation (CR).
Methods: The clinical effectiveness of a 2-week disease-related expressive writing procedure (writing about one’sd e e p e s t
thoughts and feelings regarding the experience with heart disease) compared with the standard writing task (writing
about one’s deepest thoughts and feelings about the most traumatic or negative event experienced in the life), a neutral
writing condition (writing about the facts regarding heart disease and its treatment) and an empty control condition will
be evaluated in a randomized controlled clinical trial (RCT) with repeated follow-up measurements at 3, 6 and 12 months
after discharge from CR. The primary outcome is health-related quality of life (SF-12). Secondary outcome measures are
depression (BDI-II), anxiety (BAI) and post-traumatic growth ( P T G I ) .F u r t h e r m o r e ,t h es t u d yw i l le x p l o r et h em o d e r a t i n g
effects of coping styles, type D personality, perceived emotional support and participants’ evaluative ratings of the writing
interventions on the main experimental effects in order to identify sub-groups of patients showing different results.
Discussion: The WRITTEN-HEART study aims to explore and expand the frontiers of the expressive writing research
enterprise by investigating the feasibility, safety and clinical efficacy of brief and cost-effective expressive writing
interventions in patients with CHD referred to CR.
Trial registration: ClinicalTrials.gov NCT01253486
Background
The World Health Organization (WHO)’ss t a t i s t i c ss u g -
gest that cardiovascular diseases (CVDs) are the number
one cause of mortality for all males and females,
accounting for almost 30% of all global deaths [1].
Despite this alarming scenario, the age-adjusted cardio-
vascular (CV) death rates have decreased almost 50%
during the past 25 years [2]. Improved management of
acute myocardial infarction (MI), earlier diagnostic pro-
cedures, advanced intervention techniques and especially
the recognition and management of CV risk factors have
resulted in an increasing number of CVD survivors [3].
However, such gains in survival rates have resulted in a
significant increase in physical disability, impaired
health-related quality of life and high psychosocial dis-
tress, particularly in the rapidly growing population of
elderly persons [4,5].
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within cardiac populations and contribute significantly to
impair health-related quality of life and also to enhance
the prognostic risk for adverse CV events [5]. For example,
t h ep r e v a l e n c er a t eo fm a j o rdepression disorder in the
National Comorbidity Survey [6] was approximately 5%,
compared with a prevalence of 15% or greater in popula-
tions with CVD [7]. In addition, at least another 15% to
20% of patients with cardiac disease exhibit depressive
symptoms that do not necessarily meet criteria for major
depressive disorder [7]. Similarly, anxiety disorders, such
as phobic anxiety or panic disorder, are relatively common
among patients with CVD. As a consequence, cardiologists
are likely to encounter a significant number of psychologi-
cally distressed patients in medical practice [5]. Clinical
health psychologists have thus an important role in help-
ing to develop effective psychosocial interventions for this
population [8,9].
Study rationale
A number of controlled experiments have demonstrated
the physical and psychosocial benefits of expressive writ-
ing. Developed by Pennebaker and Beall [10], the proce-
dure typically involves random assignment of individuals
to one of two conditions, with instructions to write about
their deepest thoughts and feelings regarding a stressful
experience or about innocuous topics (control) over sev-
eral brief writing sessions.
A recent special issue of the British Journal of Health
Psychology edited by Joshua Smyth and James Pennebaker
[11] confirms the breath of current interest in the expres-
sive writing paradigm and invites to look forward at the
many remaining frontiers in Expressive Writing research.
One of the boundary conditions that have been identified
in their commentary paper concerns new outcome mea-
sures and previously unexamined populations. Surpris-
i n g l y ,t h ee x p r e s s i v ew r i t i n gp r o c e d u r eh a sn e v e rb e e n
used with patients with CVD. Perhaps, clinical researchers
have been negatively impressed by some negative results
[12]. Furthermore, in a review on the putative theories
underlying the expressive writing procedure, Sloan and
Marx concluded that it was too early to say definitively
whether expressive writing is a trustworthy technique that
should be adopted by the therapeutic community [13].
However, the meta-analysis by Frisina, Borod and Lepore
[14] on 9 writings studies using clinical populations
showed that expressive writing significantly improved
health outcomes (d = .19) and the strongest effect was
found for physical health outcomes (d = .21). Moreover,
the expressive writing procedure is tremendously cost-
effective, easy to administrate, feasible and brief, does not
need highly trained clinicians to work, has a great accessi-
bility and has shown an amount of promising objective
and subjective health benefits in many studies on college
students and individuals from the community. Such
appealing features have made it very attractive for some
clinicians and clinical researchers who, beginning in the
90s and going on until nowadays, have started to use the
expressive writing procedure with their patients and to
examine its effects empirically in many randomized clini-
cal trials involving individuals with physical disorders such
as breast cancer [15-18], rheumatoid arthritis [19], fibro-
myalgia [20], HIV [21,22], renal cell carcinoma [23], men
diagnosed with prostate cancer [24], women with chronic
pelvic pain [25], men with elevated blood pressure [26],
patients undergoing bladder papilloma resection [27] and
transurethral prostate resection [28].
The fact that no trial to date has yet evaluated the effects
of expressive writing on patients with CVD is surprising
because many studies on the physiological effects of
expressive writing have found significant and beneficial
variations in many markers of the autonomic nervous sys-
tem such as skin conductance, heart rate, heart rate varia-
bility and blood pressure [e.g., [17]]. It is even more
disappointing that the small but significant study of
McGuire, Greenberg and Gevirtz [26] on the autonomic
effects of expressive writing in individuals with elevated
blood pressure has been neither replicated nor expanded
in the subsequent years. In their paper, McGuire, Green-
berg and Gevirtz argued that, given the high costs and
potential risks of elevated blood pressure and the lack of
demonstrated effective non-pharmacological treatments
for this population, a low-cost and easily administered psy-
chological intervention as expressive writing, if shown to
be effective, has the potential for widespread clinical use.
Although they showed that, one month after writing, the
participants who were allocated in the expressive writing
condition exhibited lower systolic and diastolic blood pres-
sure than before writing and that, four months after writ-
ing, diastolic blood pressure remained lower than baseline
levels, their argument felt on deaf ears. As elevated blood
pressure is a major neuro-cardiovascular risk factor that
often affects patients with an established CVD, an intri-
guing idea is to administer the expressive writing proce-
dure to a sample of patients with CVD referred to cardiac
rehabilitation (CR) and test the brief, mid and long-term
effects of such an intervention on patients’ health-related
quality of life (HRQoL), anxiety symptoms, depressive
symptoms, medical consultations for cardiovascular mor-
bidity and post-traumatic growth. With respect to the lat-
ter outcomes, same evidence suggests that expressive
writing is effective in enhancing positive growth from
trauma over time [29] and a body of research has shown
that awareness of the benefits of adverse events and cir-
cumstances is an important predictor of successful adjust-
ment [30-32].
Further empirical support to the rationale of this study
comes from the results of a recent clinical trial on
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isms underlying the positive health effects produced by
disease-related expressive writing in a sample of women
with early stage breast cancers [17]. Findings supported
the hypothesis that autonomic activity (heart rate) med-
iates the effect of the expressive writing condition on
self-reported physical symptoms. Findings suggested
that the prolonged and repeated exposure and concomi-
tant cognitive processing might contribute to improved
regulation of physiological responses, presumably lead-
ing to less stress on bodily systems and ultimately
enhanced physical health [17].
A second goal of the study is to determine whether the
effects of the expressive writing intervention vary as a
function of four potential moderating variables: coping
styles, negative affectivity and social constraint (type D
personality factors), perceived social support and evalua-
tive ratings of the writing intervention. In fact, some evi-
dence suggests that expressive writing may be most
effective for individuals who use more approach-oriented,
expressive coping strategies than for those who are more
non-expressive or have deficits in identifying and proces-
sing emotion [33-35]. Further, same evidence suggests that
perceived emotional support is a moderator of the expres-
sive writing effects. This hypothesis was guided by social
constraint theory, which suggests that the absence of social
outlets for emotional expression and processing has a
negative effect on adjustment to stressful situations and
that expressive writing may represent a useful intervention
for individuals who lack opportunities for emotional
expression in their social environments [36].
Methods
Study design
A four-arm randomized controlled clinical trial with four
follow-up assessments (immediately before discharge from
hospital, 3 months, 6 months and 12 months after dis-
charge) will be carried out in order to test the following
primary hypotheses/outcomes: 1) a modified disease-
related expressive writing intervention is effective in
enhancing physical and psychological health outcomes
(HRQoL, anxiety and depression symptoms, medical visits
for CVD-related morbidities) relative to a sham condition
in which patients write solely about the facts of their
experience with CVD and relative to a control empty con-
dition; 2) the modified disease-related expressive writing
intervention is more effective in enhancing physical and
psychological health outcomes than a standard expressive
writing condition in which patients write about the their
deepest thoughts and feelings about the most traumatic or
negative event they have experienced in their life. Further
hypotheses/outcomes concern post-traumatic growth and
are: 1) the modified disease-related expressive writing
intervention is effective in enhancing post-traumatic
growth relative to sham and control conditions; 2) the
modified disease-related expressive writing intervention is
more effective in enhancing post-traumatic growth than
the standard expressive writing task.
Secondary analyses will be conducted in order to explore
the relative efficacy of the writing conditions as a function
of patients’ gender, age, coping styles, negative affectivity
and social constraint (type D personality factors), per-
ceived social support and evaluative ratings of the writing
intervention. Accordingly, significant interactions between
the experimental conditions and the moderator variables
mentioned above are postulated such that, for example,
patients low on avoidance will benefit more from expres-
sive writing than avoidant patients and that patients per-
ceiving low social support will benefit more than patients
perceiving high social support.
The Medical Ethics Committee of Istituto Auxologico
Italiano approved the study protocol.
Study population
Recruitment of participants and selection criteria
All coronary patients who will be referred to the S. Giu-
seppe Hospital of the Istituto Auxologico Italiano for resi-
dential cardiac rehabilitation (CR) and who will meet
inclusion criteria of having had a medical diagnosis of Cor-
onary Heart Disease (CHD) and being affected by major
cardiovascular risk factors will be asked and screened for
admission in the study. CHD is defined as a history of at
least one of the following conditions: myocardial infarction,
coronary artery by-pass grafting (CABG) and coronary
angioplasty (PTCA). Patients will not be selected if they
will be diagnosed with recent (less than four weeks) myo-
cardial infarction, CABG or PTCA, if they will be unable
to read and write in Italian and if they will have an age
≥ 70 years.
Randomization procedure and blinding
All participants will be randomly assigned to the experi-
mental conditions in a consecutive way. The simple ran-
domization scheme will be generated by using the Web
site http://www.randomization.com. Random allocation
will take place after the baseline measurements and
patients will be blind to condition assignment.
Sample size calculation
Given that no study has yet evaluated the health effects of
expressive writing on patients with CVD and considering
the small mean effect sizes calculated by Frattaroli in her
meta-analysis on expressive writing studies [37], no
appropriate and reasonable empirical data are available
for calculating the necessary sample size that would
allow a high chance to detect a significant difference
across conditions. Because of this, the study may be con-
sidered partially explorative and a very large sample (the
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Frattaroli in her meta-analysis) is thus not needed.
Hence, calculations were based on the explorative
assumption that the effect of expressive writing on cor-
onary patients’ health-related quality of life is large (f =
0.4) in accordance to Cohen’s classification [38]. We
further decided not to make assumptions on sidedness
because the expressive writing procedure may also have
negative effects in comparison with the control empty
group. On the basis of such considerations, a total sample
of 92 participants (n = 23 for each condition) is required
taking into account a total dropout rate of 20% to detect
this large difference with an alpha of 0.05 two-sided and
a power of 0.82. Calculations were made with Sample-
Power (Release 2.0; SPSS, Inc., Chicago, IL).
Experimental and clinical protocol
Patients will be recruited from a residential cardiovascu-
lar rehabilitation unit in the northwestern of Italy. The
cardiac rehabilitation (CR) program lasts 1 month for
each patients in accordance with the Italian Health
Institute’s guidelines. Along this period, patients live in
the S. Giuseppe hospital, which is located on a moun-
tain highland and far away from towns and cities. Few
days after entry in the CR unit and immediately after
the initial medical evaluation and treatment planning
(first week), patients will be approached by the research
investigator for initial screening in accordance to inclu-
sion and exclusion criteria. Patients who will go through
the screening will be informed orally by the research
investigator that a scientific study is ongoing and that
its purpose is “to learn more about how individuals
adjust to having heart disease”.T h e yw i l lb ea l s ot o l d
that they could be asked to write about their experi-
ences with heart disease and, if they will consent, they
will be scheduled for the following day when they will
receive the informed consent form, which includes no
mention of expected benefits from the writing sessions
and no mention of the randomization to one of four
conditions. Once patients will have signed the informed
consent form, they will be administered the baseline
questionnaires. With the exception of the control parti-
cipants, they will receive a schedule relative to the four
writing sessions to be completed within the following
two weeks. Once randomization will be performed, no
change in treatment allocation will take place in the
future. Participants will complete the individual writing
sessions in a peaceful laboratory close to the CR unit.
Writing instructions will be written on the sheets that
patients will use to write and will be presented to them
at the beginning of each writing session. A research
assistant will meet with each participant just before
writing, will give him the writing sheets and will let him
alone in the laboratory for twenty minutes, then she will
return to stop the session and to pick up the sheets.
Participants will be randomized to one of the following
four conditions: 1) disease-related expressive writing
(DS-EW); 2) standard expressive writing (S-EW); 3) une-
motional writing (Sham) and 4) an empty condition not
involving a writing task (assessments only). All the active
conditions (1, 2 and 3) will consist in four 20-minute
writing sessions that will occur during the hospital stay
within a 2-week period and that will be scheduled twice a
week for each participant.
Writing instructions for the three active groups will be
as follows:
At the end of the CR program and before discharge, all
participants, including those assigned to the empty con-
trol condition, will be re-administered the outcome ques-
tionnaires and will be told that they will receive other
follow-up questionnaires by mail at 3, 6, 9 and 12 months
after discharge from hospital. A form on which to record
any medical visits or events over the previous 3 months
will be also sent at each participant at each follow-up
assessment.
1. Disease-related expressive writing (DS-EW)
“What I would like you to write about for these four
sessions are your deepest thoughts and feelings about
your experience with heart disease. I realize that indivi-
duals with heart disease experience a full range of
emotions and I want you to focus on any and all of
them. In your writing, I want you to really let go and
explore your very deepest emotions and thoughts. You
might think about all the various feelings and changes
that you experienced before being diagnosed, after
diagnosis, during treatment, and now. Whatever you
choose to write, it is critical that you really focus on
your deepest thoughts and feelings. Ideally, I would
like you to focus on feelings, thoughts or changes that
you have not discussed in great detail with others. You
might also tie your thoughts and feelings about your
experiences with heart disease to other parts of your
life - your childhood, people you love, who you are or
who you want to be. Again, the most important part of
your writing is that you really focus on your deepest
emotions and thoughts. The only rule we have is that
you write continuously for the entire time. If you run
out of things to say, just repeat what you have already
written. Don’t worry about grammar, spelling or sen-
tence structure. Don’t worry about erasing or crossing
things out. Just write.”
2. Standard expressive writing (S-EW)
“What I would like you to write about for these four
sessions are your deepest thoughts and feelings
about the most traumatic or negative experiences
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live a traumatic experience have a full range of emo-
tions and I want you to focus on any and all of
them. In your writing, I want you to really let go
and explore your very deepest emotions and
thoughts. Whatever you choose to write, it is critical
that you really focus on your deepest thoughts and
feelings. Ideally, I would like you to focus on feel-
ings, thoughts or changes that you have not dis-
cussed in great detail with others. You might also tie
your thoughts and feelings about your negative
experiences to other parts of your life - your child-
hood, people you love, who you are or who you
want to be. Again, the most important part of your
writing is that you really focus on your deepest emo-
tions and thoughts. The only rule we have is that
you write continuously for the entire time. If you
run out of things to say, just repeat what you have
already written. Don’t worry about grammar, spelling
or sentence structure. Don’t worry about erasing or
crossing things out. Just write.”
3. Unemotional writing (Sham)
“What I would like you to write about for these four
sessions is a detailed account of facts regarding your
heart disease and its treatment. I am interested in
how the specifics of detection, diagnosis and treat-
ment differ among individuals with heart disease;
therefore, it is critical that you provide an extremely
detailed account of all that happened to you with
regard to having heart disease. I realize that indivi-
duals with heart disease experience many emotions,
but in your writing I want you to focus only on the
facts, not on your emotions. No fact is too big or too
small. You might write about when your hear disease
was discovered and who discovered it, appointments
that you had with doctors or other people about your
heart disease, information you were given and what
treatment was chosen. You might recount your
experience from beginning to present day, including
all the factual details you can think of. Again the
most important part of your writing is that you focus
on the facts and try to reconstruct what happened in
as great factual detail as possible. The only other rule
... [Instructions continue as above]
Outcome Measures
SF-12
T h eS F - 1 2H e a l t hS u r v e yi sam e a s u r eo fp h y s i c a la n d
mental health. It is the short form of the most popular
SF-36 and consists of the 12 items that were found to
be the best predictors of the two SF-36 physical and
mental summary scores (referred to as PCS-36 and
MCS-36, respectively) in the US validation study [39].
Selected items and weights derived from the general US
population were then used to score the physical and
mental summary scores (referred to as PCS-12 and
MCS-12, respectively). The PCS-12 and MCS-12 were
very highly correlated with PCS-36 and MCS-36 (r =
0.951 and 0.969, respectively) and were very weakly cor-
related (r = 0.06) with each other in the US sample. In
the present study, the Italian version of the SF-12 will
be used [40] and the two summary scores (PSC-12 and
MCS-12) will be computed with weights derived from
the Italian validation sample.
Beck Depression Inventory - II
The Beck Depression Inventory - Second Edition (BDI-II)
is a measure of depressive symptoms. It was developed by
revising the BDI in response to the American Psychiatric
Association’s publication of the Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition, which chan-
ged many of the diagnostic criteria for Major Depressive
Disorder. Indeed, the BDI items involving changes in body
image, hypochondria and difficulty working were replaced.
Also, sleep loss and appetite loss items were revised to
assess both increases and decreases in sleep and appetite.
All but three of the items were reworded; only the items
dealing with feelings of being punished, thoughts about
suicide and interest in sex remained the same. Finally,
respondents rate how they have been feeling for the past
two weeks, as opposed to the past week as in the original
BDI. Like the BDI, the BDI-II also contains 21 items and
each answer is scored on a scale that ranges from 0 to 3.
A total score is computed by summing all the ratings and
higher total scores indicate more and more acute depres-
sive symptoms. The Italian study to establish the validity
and reliability of the measure indicated that the BDI-II is
positively correlated with the Hamilton Depression Rating
Scale. The test was also shown to have a high one-week
test-retest reliability (Pearson r = 0.93), suggesting that it
was not overly sensitive to daily variations in mood. The
test also has high internal consistency (a =. 9 1 ) .
Beck Anxiety Inventory
The Beck Anxiety Inventory (BAI) is a measure of anxi-
ety symptoms. It consists of 21 items that represent 21
psychological or somatic symptoms of anxiety (such as
numbness, hot and cold sweats or feelings of dread).
The respondent is asked to rate on a scale which ranges
from 0 (N o ta ta l l )t o4( SEVERELY: I could barely
stand it) how each symptom has caused him distress in
the previous week. A total score is computed by sum-
ming all the ratings and higher total scores indicate
more and more severe anxiety symptoms.
Post-Traumatic Growth Inventory - Short Form
The Post-Traumatic Growth Inventory - Short Form
( P T G Y - S F )w a sd e r i v e da n a l y tically from the 21-item
PTGY [41] and consists of the 10 items that loaded most
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the items with the highest loadings on each factor were
examined and the two with the highest loadings were
selected for three (Spiritual Change, Appreciation of Life
and Personal Strength) of the five factors. For the
remaining two factors (Relating to Others and New Pos-
sibilities) the two items with the highest loadings were
not selected because they were too redundant in content;
instead items were selected in order to improve the
breadth of coverage. In the US validation study, the 10-
item PTGI-SF had internal reliability only very slightly
lower than the full form PTGI, and the reliability of the
total score was generally in the range of .90 across a vari-
ety of samples [42]. In the present study, the Italian
translation of the PTGY-SF 10 items were used [43] and
a total score for each participant was computed by aver-
aging the responses to all the items.
Frequency of medical visits for cardiovascular morbidity
A form on which to record any medical visits over the pre-
vious 3 months will be also sent at each participant at the
four follow-up time points. Patients have to retrospectively
record all medical visits during the previous 3 months.
They have to record also the medical provider and the rea-
son for each visit (e.g., check-up with medical cardiolo-
gist). These medical appointments will be coded as
a function of reason for the visit (i.e., routine and non-rou-
tine CVD-related and non-CVD-related appointments) by
the research investigator who will be aware of participants’
condition assignment. Medical appointments for CVD-
related problems will be of interest, excluding scheduled
check-ups, as an indicator of morbidity associated with
CVD and its treatment. The other categories of medical
appointments (i.e., CVD-related scheduled medical check-
ups, other scheduled medical check-ups or non-routine
medical appointments for other problems, such as flu
symptoms) will be combined for analysis.
Covariates
CVD-related past and actual perceived stress
Along with the collection of demographic and clinical
data and before the questionnaires’ administration,
patients will be asked to rate how much stressful was the
CVD onset and how much stressful is currently the CVD
on seven-point scales from (1) not at all to (7) extremely.
Writing ratings
Immediately following the last writing session, participants
will be asked to rate sixteen items reflecting some aspects
of the writings and of the whole writing experience on
seven-point scales from (1) not at all to (7) extremely. For
example, participants will be asked to rate how emotional
and how personally meaningful the essays were.
Self-reported mood
Immediately prior to and after each writing session, par-
ticipants will complete a restricted and “right now”
version of the Profile of Mood States (POMS). The scale
has 65 affect adjectives rated on a 7-point scale (0 not
at all, 7 extremely). As in other studies [17,34,44], we
will construct a distress index (Distress) by adding items
(e.g., tense, sad) on the Anger, Depression, Tension,
Fatigue and Confusion subscales, and we will use the
Vigor subscale (e.g., energetic, cheerful) to indicate posi-
tive mood.
Type D Personality Inventory
T h eT y p eDP e r s o n a l i t yS c a l e( D S 1 4 )i sa1 4 - i t e ms c a l e
comprising of two subscales [45]: a seven-item subscale
which measures negative affectivity (NA) (e.g., “I often feel
unhappy”) and a 7-item subscale measuring social inhibi-
tion (SI) (e.g., “I often feel inhibited in social interactions”).
Respondents rate their personality on a five-point Likert-
type scale which ranges from 0 = false to 4 = true (Items 1
and 3 were reverse scored). The NA and SI scales can be
scored as continuous variables (range, 0-28) to assess
these personality traits independently. Participants who
s c o r eh i g h l yo nb o t hN Aa n dS Iu s i n gac u t o f fp o i n to f
≥10 on both scales are classified as having a Type D
personality.
Brief COPE
The Brief COPE is a self-completed questionnaire measur-
ing coping strategies [46]. It is the short form of the most
famous 60-item COPE inventory (15 scales with 4 items
per scale) and consists of 28 items that compose 14 scales
of two items each. Two scales from the full measure were
omitted from the brief form because they did not proven
useful in previous work or had proven redundant with
another scale (Restraint Coping and Suppression of Com-
peting Activities). Three other scales were refocused
slightly because they had proven to be problematic in pre-
vious work. Positive Reinterpretation and Growth became
Positive Reframing (omitting any mention of growth),
Focus on and Venting of Emotions became Venting (omit-
ting items that had appeared to relate too closely to
experiencing distress) and Mental Disengagement became
Self-Distraction. A new scale (self-blame) - not part of the
original COPE - was added because of evidence of its
importance [46]. Respondents rate each item on a four-
point Likert scale which ranges from 1 (I usually do not
this at all)t o4( Iu s u a l l yd or i g h tl i k et h i s ). Items and
response options can be converted to a dispositional “cop-
ing style” format (the one I used for the present study) and
to a situational concurrent format. The first study to
establish the validity and reliability of the measure indi-
cated that the a priori scales had adequate internal reliabil-
ity (from a = 0.82 for Religion to a = 0.54 for Denial) and
that the factor structure was generally consistent with that
reported for the full COPE [46]. In the present study, the
Italian version of the Brief COPE will be used [47] and the
1 4s c a l es c o r e sw i l lb ec o m p u t e db ya v e r a g i n gt h e
responses to the two composing items.
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A ni n d e p e n d e n tr a t e rn o ti n v o l v e di nt h es t u d ya n d
unaware of condition membership will judge whether
each writings, randomly ordered, will conform to condi-
tion instructions.
Statistical analysis
Data entry will be conducted by a trained research assis-
tant who will be aware of participants’ condition assign-
ment but not of the research hypotheses. Preliminary
analyses will be performed to examine assumptions for
parametric statistical analysis and baseline equivalence
among groups. Given the longitudinal nature of the data
(repeated measurements), multilevel modeling analysis in
MLwiN 2.21 (Centre for Multilevel Modeling-CMM, Uni-
versity of Bristol) will be used to study health outcomes
(physical and mental health, anxiety, depression, post-trau-
matic growth and number of medical visits for cardiovas-
cular morbidity) as functions of time and experimental
conditions. This will allow testing of experimental hypoth-
esis as cross-level interactions between slopes representing
time (1
th level) coded as 0 for the first (immediately before
discharge from hospital) follow-up, as 1 for the second (3-
month) follow-up, as 2 for the third (6-month) follow-up
and as 3 for the fourth (12-month) follow-up, and a cate-
gorical covariate representing conditions (2
nd level). We
will start with a simple random intercept model (for calcu-
lating intra-class correlation [ICC]) and a simple linear
growth model, followed by a model with experimental
conditions as a time-invariant covariate. We then will
structure more complicated models, including models
with different within-individual covariance structures and
models with nonlinear growth patterns. A critical alpha of
0.05 will be considered for hypothesis testing. Further-
more, on the basis of the best multilevel models structured
in the primary analyses, we will explore the moderating
effects of some putative covariates at level 2 such as gen-
der, age, coping styles, negative affectivity and social inhi-
bition (Type D personality dimensions), perceived social
support and writings ratings. For these secondary explora-
tive analyses no level of significance will be defined. Read-
ers interested in further discussion of analyzing
longitudinal data with multilevel modeling analysis are
referred to an excellent guide by Kwok et al. [48] as well
as a thorough treatment of the issue by Singer and Willett
[49].
Discussion
For the first time the expressive writing procedure will
be administered to a sample of patients with CVD
referred to a 3-week residential cardiac rehabilitation
program. The feasibility, safety and clinical efficacy of
such a brief psychological intervention will be evaluated
in a four-arm randomized controlled clinical trial with a
12-month follow-up period. Multiple psychological vari-
ables relevant to patients with CVD will be assessed in
order to examine the specific effects of the expressive
writing intervention on some psychosocial risk factors
related to CV morbidity in this population. Furthermore,
a generic measure of health-related quality of life
(HRQoL) will be administered to participants at each
follow-up assessment as HRQoL improvement is among
the major outcomes of clinical trials [50] and was estab-
lished as one of the primary goals of cardiac rehabilita-
tion [51].
Given the novelty of the study and our will to handle a
low number of outcomes, physiological data such as heart
rate, blood pressure and cholesterol will not be considered
for the analyses and only a measure of medical visits or
events along the follow-up period will be used as a surro-
gate marker of bio-medical health.
This study is essentially intended to explore and expand
the clinical frontiers of the expressive writing research
enterprise. Altough no advancement in the theorical
knowledge about the multi-level mechanisms that underlie
the expressive writing task is scheduled, the results of this
trial will contribute to the evidence-based knowledge on
the application of the expressive writing procedure for
clinical purposes in clinical settings [52].
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